Trichostatin A
WikiDoc Resources for Trichostatin A |
Articles |
---|
Most recent articles on Trichostatin A Most cited articles on Trichostatin A |
Media |
Powerpoint slides on Trichostatin A |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Trichostatin A at Clinical Trials.gov Trial results on Trichostatin A Clinical Trials on Trichostatin A at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Trichostatin A NICE Guidance on Trichostatin A
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Trichostatin A Discussion groups on Trichostatin A Patient Handouts on Trichostatin A Directions to Hospitals Treating Trichostatin A Risk calculators and risk factors for Trichostatin A
|
Healthcare Provider Resources |
Causes & Risk Factors for Trichostatin A |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Trichostatin A is an organic compound that serves as an antifungal antibiotic and selectively inhibits the mammalian histone deacetylase family of enzymes. TSA inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin. Thus, TSA has some uses as an anti-cancer drug. By promoting the expression of apoptosis-related genes, it may lead to cancerous cells surviving at lower rates, thus slowing the progression of cancer.